Last Updated : June 17, 2024
Details
FilesGeneric Name:
enfortumab vedotin
Project Status:
Active
Therapeutic Area:
Metastatic urothelial cancer
Manufacturer:
Seagen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Padcev
Project Line:
Reimbursement Review
Project Number:
PC0353-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
In combination with pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
In combination with pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | April 09, 2024 |
|---|---|
| Call for patient/clinician input closed | June 03, 2024 |
| Submission received | May 22, 2024 |
| Submission accepted | June 05, 2024 |
| Review initiated | June 06, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | August 21, 2024 |
| Deadline for sponsors comments | August 30, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | September 26, 2024 |
| Expert committee meeting (initial) | October 09, 2024 |
| Draft recommendation issued to sponsor | October 22, 2024 To October 24, 2024 |
| Draft recommendation posted for stakeholder feedback | October 31, 2024 |
| End of feedback period | November 15, 2024 |
Files
Last Updated : June 17, 2024